<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362712">
  <stage>Registered</stage>
  <submitdate>3/07/2012</submitdate>
  <approvaldate>17/07/2012</approvaldate>
  <actrnumber>ACTRN12612000760875</actrnumber>
  <trial_identification>
    <studytitle>UREMIC TOXIN: Utility in REnal disease of Measuring Indoxyl sulphate and p-Cresyl sulphate To predict OXidative stress, Inflammation and cliNical outcomes</studytitle>
    <scientifictitle>A retrospective cross-sectional/longitudinal observational study looking at the concentration of uremic toxins with poor outcomes in patients with Chronic Kidney Disease Stage 1-5</scientifictitle>
    <utrn>U1111-1132-3596</utrn>
    <trialacronym>Uremic Toxin</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Kidney Disease</healthcondition>
    <healthcondition>Cardiovascular disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chronic Kidney Disease level of uremic toxins (serum analysis), CVD biomarkers (arterial stiffness by aortic pulse-wave velocity (PWV); atheroma burden by carotid intima-media thickness (cIMT) and endothelial function by flow-mediated dilation (FMD) of the brachial artery), and inflammation (serum markers) for two years.

All of the above will be performed at three time points baselines, 1 year and 2 year.</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Indoxyl sulphate concentration (mg/L) (serum analysis)</outcome>
      <timepoint>baseline, year 1, year 2</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>P-cresyl sulphate concentration (mg/L) (serum analysis)</outcome>
      <timepoint>baseline, year 1, year 2</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular risk factors- arterial stiffness by aortic pulse-wave velocity (PWV); atheroma burden by carotid intima-media thickness (cIMT) and endothelial function by flow-mediated dilation (FMD) of the brachial artery.</outcome>
      <timepoint>baseline, year 1, year 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality- all cause and cardiovascular (death registry)</outcome>
      <timepoint>study duration ie. 0-2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Kidney Function- serum creatinine (serum analysis), urinary protein (mid stream urinary analysis)</outcome>
      <timepoint>baseline, year 1, year 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Inflammation- C-Reactive Protein, Interleukin-6 (serum analysis)</outcome>
      <timepoint>baseline, year 1, year 2</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic Kidney Disease (CKD) (stage1-5D)
&gt;/= 18 years
Able to provide informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Non CKD
Unable/unwilling to give informed consent
Unable/unwilling to comply with frequent follow-up
Life expectancy was severely limited due to pre-existing malignancy or other disease (&lt;6 months) 
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Princess Alexandra Hospital</primarysponsorname>
    <primarysponsoraddress>199 Ipswich Rd Woolloongabba, Brisbane, Queensland 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Princess Alexandra Hospital</fundingname>
      <fundingaddress>199 Ipswich Rd Woolloongabba, Brisbane, Queensland 4102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Queensland</othercollaboratorname>
      <othercollaboratoraddress>Mansfield Place St Lucia, Brisbane, Queensland 4072</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The roles of indoxyl sulphate and p-cresyl sulphate as nephro- and cardiovascular toxins has recently gained recognition, although their true association and mechanisms behind their putative deleterious actions are yet to be investigated in human studies.	
The aim of this observational study is to gain a better understanding of the associations between these two protein-bound uremic toxins, IS and PCS, and Cardio Vascular Disease (CVD) and CKD progression, along with other poor outcomes seen in CKD. A secondary
 aim is to determine whether live kidney donors post nephrectomy have an increase concentration of these toxins and any association with morbidity in this population.</summary>
    <trialwebsite />
    <publication>Rossi M,  Klein K,  Johnson DW, and Campbell KL. (2012).Pre-, Pro- &amp; Synbiotics: Do they have a role in reducing uremic toxins? A systematic review and Meta analysis. British Journal of Nutrition (under review)</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Metro South Hospital and Health Service</ethicname>
      <ethicaddress>199 Ipswich Rd, Woolloongabba, Brisbane, Queensland 4102</ethicaddress>
      <ethicapprovaldate>4/05/2012</ethicapprovaldate>
      <hrec>HREC/12/QPAH/216</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Megan Rossi</name>
      <address>ARTs Building 31, 2nd Floor Nephrology Building.
199 Ipswich Rd, Brisbane, Queensland 4102</address>
      <phone>+614 02931441</phone>
      <fax>+61 7 3176 5480</fax>
      <email>megan_rossi@msn.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Megan Rossi</name>
      <address>ARTs Building 31, 2nd Floor Nephrology Building.
199 Ipswich Rd, Brisbane, Queensland 4102</address>
      <phone>+614 02931441</phone>
      <fax>+61 7 3176 5480</fax>
      <email>megan_rossi@msn.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Megan Rossi</name>
      <address>ARTs Building 31, 2nd Floor Nephrology Building.
199 Ipswich Rd, Brisbane, Queensland 4102</address>
      <phone>+614 02931441</phone>
      <fax>+61 7 3176 5480</fax>
      <email>megan_rossi@msn.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>